August 26th 2025
The study will be evaluating the safety, tolerability, and efficacy of QLS-111 in adult patients with normal tension glaucoma.
Nicox and Kowa sign agreement for exclusive rights to glaucoma treatment NCX 470
July 20th 2025Under the terms of the agreement, Kowa receives exclusive rights to develop and commercialize NCX 470 in the US and all other territories of the world excluding Japan, China, Korea, and Southeast Asia.
Read More